Recruiting INTERVENTIONAL NCT05910827

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

A Phase Ib/II Study to Evaluate HMBD-001 in Combination With Cetuximab, With or Without Docetaxel in Participants With Advanced Squamous Cell Carcinomas

Sponsor: Hummingbird Bioscience

Conditions Advanced Cutaneous Squamous Cell Carcinoma Advanced Esophageal Squamous Cell Carcinoma Advanced Head and Neck Squamous Cell Carcinoma Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Cervical Squamous Cell Carcinoma Nasopharyngeal Cancinoma (NPC) Squamous Cell Carcinoma

Interventions Cetuximab Docetaxel HMBD-001

Updated 16 times since 2023 Last updated: Apr 13, 2026 Started: Feb 5, 2024 Primary completion: Dec 1, 2027 Completion: Dec 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05910827, this observational or N/A phase trial focuses on Advanced Cutaneous Squamous Cell Carcinoma and Advanced Esophageal Squamous Cell Carcinoma and remains actively recruiting participants. Sponsored by Hummingbird Bioscience, it has been updated 16 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

16 versions recorded

Apr 16, 2026 — Present [daily]

Recruiting

Phase: PHASE1/PHASE2 → None
Dec 2025 — Apr 2026 [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
May 2025 — Jul 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 11 earlier versions

Mar 2025 — May 2025 [monthly]

Recruiting PHASE1/PHASE2
Nov 2024 — Mar 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE1_PHASE2
Dec 2023 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2023 — Oct 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Jul 2023 — Sep 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers

Contact Information

Sponsor contact:

Hummingbird Bioscience
Merck KGaA, Darmstadt, Germany

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Brisbane, Australia , Cheongju-si, South Korea , Chisinau, Moldova , Frankston, Australia , Greenslopes, Australia , Kaohsiung City, Taiwan , Malvern, Australia , Perth, Australia , Seongnam-si, South Korea and 10 more locations